TCR-T cell therapy (RHOT2 neoantigen-specific)

TCR-T cell therapy (RHOT2 neoantigen-specific) is an adoptive cellular immunotherapy involving primary human T cells engineered to express a T-cell receptor (TCR) specific for a neoantigen derived from the RHOT2 gene. This neoantigen is generated by recurrent RNA mis-splicing (specifically intron retention) induced by mutations in the splicing factor SRSF2, which are common in myeloid neoplasms such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The TCR, originally identified from donor T cells post-allogeneic stem cell transplant, recognizes the RHOT2 neoepitope presented on HLA-A*02:01. Upon binding, the engineered T cells selectively lyse leukemic cells harboring the SRSF2 mutation while sparing normal tissues. This approach targets public neoantigens shared across patients with specific splicing factor mutations.

Other names

RHOT2-specific TCR-T cell therapyRHOT-2-specific TCR-T cell therapyRHOT 2-specific TCR-T cell therapyRHOT2 neoantigen-specific TCR-TRHOT-2 neoantigen-specific TCR-TRHOT 2 neoantigen-specific TCR-T